JAK2, integral to IL-6R signaling and linked to atherosclerosis, is being explored as a target using JAK inhibitors, primarily in myeloproliferative diseases.131 Ruxolitinib, a JAK1 and JAK2 inhibitor, demonstrated mixed effects in murine atherosclerosis models, reducing lesion size but promoting unstable plaque composition.132. This evidence concerns the gene IL6R and myeloproliferative disorder.